Three BriaCell poster presentations include updated key biomarker data from BriaCell’s pivotal Phase 3 study and updated ...
Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results from the MyPEAK™-1 Phase 1b/2a Clinical Trial in Adults with ...
Background Hypothyroidism has been suggested as a predisposing and prognostic factor in patients with spontaneous coronary ...
By implementing appropriate security measures, threat assessment protocols, and compliance-driven policies, healthcare ...
For patients across all indications treated within the RP2D range early, promising progression-free survival (PFS) and ...
Investigator-initiated study shows potential for EchoSolv AS to drive improved patient outcomes when used to support cardiologist in identifying severe AS particularly in womenNEDA study of 1.2M ...
Olema Pharmaceuticals (OLMA) surges after Roche's breast cancer data, but caution is urged as key clinical results are ...
Funding advances Phase 2 expansion cohorts in pancreatic and colorectal cancer in ATM-negative patients for Artios’ potential first-in-class ATR Inhibitor, alnodesertib Following encouraging ESMO data ...
The Global Electronic Data Capture Software Market Size projected to grow at a CAGR of 14.5% from 2024 to 2031, according to ...
Open-label prophylaxis data supporting the long-term safety profile and sustained benefits of deucrictibant, as well as clinical validation data of a kinin biomarker assay were highlighted in two oral ...
Clinical Data Demonstrating Efficacy Of Sotagliflozin In Preserved Ejection Fraction Heart Failure (Hfpef) Without Diabetes Presented At American Heart Association (AHA) Annual Scientific Sessions ...
Terns Pharmaceuticals ( ($TERN) ) has shared an announcement. On November 3, 2025, Terns Pharmaceuticals announced that data from the Phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback